FDA to reconsider removal of Lilly's GLP-1 drug from shortage list, a win for compounding pharmacies
The FDA said it will reconsider the removal of Eli Lilly’s GLP-1 drug tirzepatide from its official shortage list, after a trade group representing large …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
